Chronic Myeloid Leukemia (CML): historical perspective, pathophysiology, and treatment advances - PubMed
3 hours ago
- #BCR-ABL1
- #Tyrosine Kinase Inhibitors
- #Chronic Myeloid Leukemia
- Chronic Myeloid Leukemia (CML) was the first leukemia described in medical literature and remains a well-studied hematologic malignancy.
- Key milestones in CML research include the discovery of the Philadelphia chromosome (1960), BCR::ABL1 fusion gene (1980s), and the development of tyrosine kinase inhibitors (TKIs).
- Imatinib revolutionized CML treatment in the early 2000s, turning a fatal disease into a manageable chronic condition.
- Second- and third-generation TKIs were developed to address drug resistance and target specific mutations like T315I.
- Current research focuses on TKI resistance mechanisms, novel signaling pathways, and achieving treatment-free remission (TFR).
- Emerging therapies include vamotinib, KF1601, and combination regimens, alongside studies on non-kinase functions of BCR::ABL1 and microRNAs in resistance.